shi estimate better profit off-set
factor line rais ep guidanc
reflect share repurchas million
embed previou guid rais ep
reflect better profit trend lower share base
revenu light profit ahead plan strong btb
compar net revenu rose
compar estim though post solid net book-to-bil
well ahead plan reflect net new busi million
vs estimate million cancel rate line hist
average backlog convers tick lower like grow
mix skew toward complex studi gross margin fell bp
greater sg leverag bp bp better plan help
drive ebitda margin expans bp flow million
help fund share repurchas cash reserv stand million
share rise admittedli noth icon iclr latest
releas pleas book strength assum
repres net servic revenu estim revenu growth
excl eye-pop indic
expans larg pharma account well faster-grow smid
biopharma previou quarter sg leverag clear bright spot
topic tomorrow call underli demand cc organ growth ex
pharma consolid capit deploy ep
iclr trade premium cro peer view upsid
warrant underli busi strength profit capit
deploy driver risk includ shift demand cancellations/win
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
icon public limit compani icon ireland-bas contract
servic pharmaceut biotechnolog medic devic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat iclr assum substanti
new busi win addit project award offset
sizabl cancel increment profit margin expans
pronounc strength spend outsourc demand
grey sky valuat iclr assum greater-
than-expect declin busi largest custom
consolid capit deploy misstep weaken demand
outsourc
 close
iclr healthi net-btb came well estim
repres fifth consecut quarter btb dynam well-
receiv investor backlog convers slightli
remain industri averag dynam like attribut
prolong start-up phase certain larger client along broader impact larger
studi matur increas work complex oncolog project cancel
rate quarter rate lead million vs
million cancel
revis guidanc iclr updat ep guidanc
reflect million share repurchas previous embed
prior guidanc remind iclr ep guidanc futur share
repurchas may execut remaind also re-affirmed total
servic revenu guidanc incl pass-through million
account updat iclr guidanc reflect implement
note manag discuss servic revenu profit
metric reflect previou report standard highlight
account chang impact iclr previou ep guidanc
charl martineau pm univers toronto figur backlog convers continu impact increas mix complex therapeut area
note industri averag adjust vari definit recognit backlog less aggress depend compani
figur book-to-bil ratio momentum continu
consist elimin quarterli fluctuat calcul dso use ttm total
revenu servic revenu reimburs revenu weight averag net
receiv bill unbil less prepaid revenu trail five quarter base
calcul iclr ttm dso current stand day line previou
quarter within consid normal rang day
longer term compar industri averag gener day rang
public trade coverag
gener million cash cash reserv current stand million capit
deploy prioriti continu balanc share buyback tuck-
deal opportunist basi could provid upsid estim
iclr share current trade ep peer group clinic
reflect non-pf prospect acceler well profit
capit deploy driver broadli view iclr well-posit benefit
continu strong fundament across cro industri view upsid
forecast iclr net servic revenu increas billion
fuel increas custom diversif contribut clinic
rm mapi group partial off-set cancel ep
forecast predic ebitda margin expans bp
contribut share repurchas forecast ep growth
predic net servic revenu growth billion ebitda margin
expans bp
iclr share current trade ep estim premium histor
averag target price ep estim better reflect
opportun continu market share gain slightli temper slow backlog
burn diminish contribut profit margin leverag opportun
potenti upsid capit deploy option lowest leverag ratio
compani mention price
